About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06581549

Immune Microenvironment and Gene Expression Profiling in Mesothelioma

Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options a...

Lead sponsor: Istituto Oncologico Veneto IRCCS•10 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Giulia Pasello, MD

CONTACT

0498215608 giulia.pasello@iov.veneto.it

Gian Luca De Salvo, MD

CONTACT

0498215704 clinical.trial@iov.veneto.it

Sponsors

Lead Sponsor

Istituto Oncologico Veneto IRCCS

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with Mesothelioma of the Pleura and Peritoneum
•Age greater than 18 years of age
•Patients undergoing surgery will require both biopsy and surgical sampling material
•Pathologist's confirmation of the presence of tumor sections in the excised specimens
•Patients in follow-up from active cancer treatment for at least 6 months

Exclusion Criteria

•Inadequacy of biological material for analysis under study
•Patients not amenable to active oncologic treatment
•Patients lost to follow-up before 6 months after the end of active oncologic treatment

Related studies

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723 · Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, and more

RECRUITINGPhase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146 · Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), and more

RECRUITINGPhase 1/2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695 · Solid Tumor, Adult, Colorectal Cancer, and more

RECRUITINGPhase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697 · Mesothelioma, Neoplasms, and more

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254 · Pancreas Cancer, Lung Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 5, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment220

Start dateNov 2023

Last updatedSep 5, 2025

Condition

Mesothelioma Mesotheliomas Pleural Mesothelioma; Lung

Locations shown

Istituto Clinico Humanitas

Rozzano, Milano

Centro di Riferimento Oncologico (CRO) IRCCS

Aviano, Pordenone

Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo

Alessandria

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions